COL – Morgans rates the stock as Add
The broker maintains its Add rating and increases its target to $20.65 from $19.70.
Read More
ORG – Credit Suisse rates the stock as Neutral
Target price rises to $6.30 from $6.20. Neutral rating retained.
Read MoreRHC – Morgans rates the stock as Hold
The broker maintains its $80 target price. The Hold rating is unchanged.
Read MoreCOL – Credit Suisse rates the stock as Neutral
Neutral maintained. Target rises to $18.81 from $18.32.
Read MoreFMG – Morgans rates the stock as Hold
The broker lowers its target price to $17.90 from $19.10. Hold.
Read MoreNUF – UBS rates the stock as Buy
Buy rating retained. Target price rises to $7.90 from $6.73.
Read MoreILU – Credit Suisse rates the stock as Outperform
The broker assesses the recent sell-off opens up some value and upgrades to Outperform from Neutral. Targets raised to $13.20 from $13.00.
Read MoreNAB – Morgans rates the stock as Hold
National Australia Bank is now Morgans preferred big four bank exposure and the target price rises to $34 from $30.50. Hold.
Read MoreBPT – Macquarie rates the stock as Underperform
Underperform maintained. Target is raised to $1.58 from $1.55.
Read MoreS32 – UBS rates the stock as Buy
The broker lowers its target price to $6.00 from $6.30. Buy rating retained.
Read MoreORA – Credit Suisse rates the stock as Neutral
The company has signalled a seasonally lower profit is expected in the Americas in the June half. Neutral maintained. Target is $3.75.
Read MoreS32 – Credit Suisse rates the stock as Outperform
Outperform rating and $6 target unchanged.
Read MoreWPL – UBS rates the stock as Neutral
The broker lowers its 2023 and 2024 EPS estimates due to lower expected production. The price target falls to $32.20 from $32.90. Neutral.
Read MoreREH – Morgans rates the stock as Hold
Hold rating is maintained. The target is reduced to $18.25 from $20.10.
Read MoreCOL – UBS rates the stock as Neutral
The broker retains its Neutral rating and $17.25 target price.
Read MoreDOW – Credit Suisse rates the stock as Neutral
Credit Suisse retains a Neutral rating. Target is steady at $5.40.
Read MoreCGF – Macquarie rates the stock as Neutral
Neutral retained, target falls to $6.60 from $6.70.
Read MoreAWC – Credit Suisse rates the stock as Outperform
The Outperform rating is retained and the target price decreases to $2.00 from $2.30.
Read MoreMP1 – Morgans rates the stock as Hold
Morgans lowers its target price to $10.65 from $14.50 and maintains its Hold rating.
Read MoreWHC – Credit Suisse rates the stock as Outperform
Target price rises to $5.60 from $4.70. Outperform rating retained.
Read MoreALX – Morgans rates the stock as Hold
The Hold rating and $6.41 price target are maintained.
Read MoreHUB – Macquarie rates the stock as Outperform
The Outperform rating is retained and the target price decreases to $32.60 from $33.50.
Read MoreBXB – Credit Suisse rates the stock as Outperform
The Outperform rating is retained and the target price decreases to $13.00 from $13.25.
Read MoreSBM – Macquarie rates the stock as Outperform
The broker resumes coverage with an Outperform rating and a target price of $1.53.
Read MoreBOQ – Morgans rates the stock as Add
The Add rating and $11 target price are unchanged.
Read MoreAKE – Citi rates the stock as Buy
The Buy rating and target price of $16.00 are retained.
Read MoreAFG – Macquarie rates the stock as Outperform
Outperform rating, $2.94 target price and earnings forecasts are retained.
Read MoreVEA – Credit Suisse rates the stock as Outperform
The broker retains its Outperform rating and $2.57 target price.
Read MoreGDG – Morgans rates the stock as Add
The target price rises to $1.88 from $1.81. Add.
Read MoreAWC – Macquarie rates the stock as Neutral
Target price eases -5% to 1.90. Neutral rating retained.
Read MorePXS – Morgans rates the stock as Speculative Buy
Morgans initiates coverage of commercial stage drug development company Pharmaxis with a Speculative Buy rating and $0.58 target price.
Read MoreLVH – Morgans rates the stock as Add
The broker maintains its Add rating, while the target edges down to $0.51 from $0.54.
Read MoreWPL – UBS rates the stock as Neutral
The Neutral rating is maintained on a full valuation, and the broker prefers Santos ((STO)) in the sector. The target falls by -5% to $32.90 on reduced values for the Sangomar and Trion oil fields.
Read MoreBHP – Macquarie rates the stock as Outperform
The Outperform rating and target price of $61.00 are retained.
Read MoreSPK – Credit Suisse rates the stock as Neutral
The broker retains its Neutral rating and $4.65 target price.
Read MorePME – Citi rates the stock as Neutral
The Neutral rating is maintained, as the broker feels the current company valuation is elevated. The target of $46 is maintained.
Read MoreWHC – Morgans rates the stock as Add
The target rises to $5.20 from $3.72. Add.
Read MoreAFG – Macquarie rates the stock as Outperform
With no changes to earnings forecasts or the $2.94 target price, the broker retains its Outperform rating.
Read MoreALL – Citi rates the stock as Buy
The broker reinitiates with a Buy rating and a target price of $44.00.
Read MoreASX – Morgans rates the stock as Reduce
The broker marginally lowers its EPS forecasts and the target price edges up to $73.05 from $72.94. The Reduce rating is retained.
Read More
